These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21702163)

  • 21. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus.
    Kolterman OG
    Am J Med; 1985 Sep; 79(3B):23-33. PubMed ID: 3931459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New pharmacologic approaches to the treatment of diabetes.
    Johnson DG; Bressler R
    Spec Top Endocrinol Metab; 1984; 6():163-92. PubMed ID: 6151747
    [No Abstract]   [Full Text] [Related]  

  • 23. [Molecular mechanism of action of sulfonylureas].
    Ammon HP
    Dtsch Med Wochenschr; 1988 May; 113(21):864-70. PubMed ID: 3286184
    [No Abstract]   [Full Text] [Related]  

  • 24. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).
    Boileau P; Wolfrum C; Shih DQ; Yang TA; Wolkoff AW; Stoffel M
    Diabetes; 2002 Dec; 51 Suppl 3():S343-8. PubMed ID: 12475773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recruitment of Epac2A to Insulin Granule Docking Sites Regulates Priming for Exocytosis.
    Alenkvist I; Gandasi NR; Barg S; Tengholm A
    Diabetes; 2017 Oct; 66(10):2610-2622. PubMed ID: 28679628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do sulfonylureas influence hepatic insulin clearance?
    Groop LC; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
    Diabetes Care; 1988 Sep; 11(8):689-90. PubMed ID: 3065007
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of oral sulfonylureas on the spectrum of defects in non-insulin-dependent diabetes mellitus.
    Owens DR
    Am J Med; 1985 Aug; 79(2B):27-32. PubMed ID: 3929599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of the second-generation sulfonylurea glipizide.
    Lebovitz HE; Feinglos MN
    Am J Med; 1983 Nov; 75(5B):46-54. PubMed ID: 6369967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sulfonylurea and alpha-glucosidase inhibitor].
    Iijima T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():459-63. PubMed ID: 12387034
    [No Abstract]   [Full Text] [Related]  

  • 31. cAMP signalling in insulin and glucagon secretion.
    Tengholm A; Gylfe E
    Diabetes Obes Metab; 2017 Sep; 19 Suppl 1():42-53. PubMed ID: 28466587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of EPAC2 function using EPAC2 null Min6 sublines generated through CRISPR-Cas9 technology.
    Xu H; Yang Y; Chen Y; Mueller U; Iyer S; Presland J; Yang R; Kariv I
    Mol Cell Endocrinol; 2018 Sep; 473():114-123. PubMed ID: 29407196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epac: defining a new mechanism for cAMP action.
    Gloerich M; Bos JL
    Annu Rev Pharmacol Toxicol; 2010; 50():355-75. PubMed ID: 20055708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function.
    Niimura M; Miki T; Shibasaki T; Fujimoto W; Iwanaga T; Seino S
    J Cell Physiol; 2009 Jun; 219(3):652-8. PubMed ID: 19170062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulfonylureas and hypoglycaemia.
    Del Prato S; Aragona M; Coppelli A
    Diabetes Nutr Metab; 2002 Dec; 15(6):444-50; discussion 450-1. PubMed ID: 12678466
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update.
    Porte D; Kahn SE
    Am J Med; 1991 Jun; 90(6A):8S-14S. PubMed ID: 1872310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination insulin-sulfonylurea therapy.
    Lebovitz HE; Pasmantier R
    Diabetes Care; 1990 Jun; 13(6):667-75. PubMed ID: 2192850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination sulfonylurea-insulin therapy in the treatment of noninsulin-dependent diabetes mellitus.
    Rosenblatt J
    Conn Med; 1991 Nov; 55(11):634-6. PubMed ID: 1790695
    [No Abstract]   [Full Text] [Related]  

  • 39. The therapeutic approach to the obese maturity-onset diabetic patient.
    Lipson LG; Lipson M
    Arch Intern Med; 1984 Jan; 144(1):135-8. PubMed ID: 6362593
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term safety and efficacy of glipizide.
    Feinglos MN; Lebovitz HE
    Am J Med; 1983 Nov; 75(5B):60-6. PubMed ID: 6369969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.